Ratio Revelations: Humacyte Inc (HUMA)’s Financial Metrics in the Spotlight

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Humacyte Inc (NASDAQ: HUMA) closed the day trading at $5.20 down -4.59% from the previous closing price of $5.45. In other words, the price has decreased by -$4.59 from its previous closing price. On the day, 5.26 million shares were traded. HUMA stock price reached its highest trading level at $5.6 during the session, while it also had its lowest trading level at $5.2.

Ratios:

For a better understanding of HUMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.

On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.

On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 10 ’24 when Sebelius Kathleen sold 5,182 shares for $5.40 per share. The transaction valued at 28,004 led to the insider holds 40,276 shares of the business.

Dougan Brady W sold 288,674 shares of HUMA for $1,509,765 on Sep 10 ’24. The Director now owns 3,230,884 shares after completing the transaction at $5.23 per share. On Sep 09 ’24, another insider, Dougan Brady W, who serves as the Director of the company, sold 157,704 shares for $5.42 each. As a result, the insider received 854,756 and left with 3,519,558 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 620625152 and an Enterprise Value of 545995840.

Stock Price History:

Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $1.96. The 50-Day Moving Average of the stock is -24.59%, while the 200-Day Moving Average is calculated to be 7.16%.

Shares Statistics:

Over the past 3-months, HUMA traded about 3.31M shares per day on average, while over the past 10 days, HUMA traded about 2554350 shares per day. A total of 103.67M shares are outstanding, with a floating share count of 93.24M. Insiders hold about 22.25% of the company’s shares, while institutions hold 25.92% stake in the company. Shares short for HUMA as of 1724976000 were 11274967 with a Short Ratio of 3.41, compared to 1722384000 on 12008640. Therefore, it implies a Short% of Shares Outstanding of 11274967 and a Short% of Float of 12.45.

Most Popular